In Medical Devices, Hurry Up and Wait
Medical device and biotech executives can debate which industry segment is getting a colder shoulder from venture capitalists these days, but it's clear that device start-ups are finding it no easier to attract traditional sources of financing than their counterparts in biotech.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.